A Combination of Broadly Neutralizing HIV-1 Monoclonal Antibodies Targeting Distinct Epitopes Effectively Neutralizes Variants Found in Early Infection

Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Journal of Virology (Impact Factor: 4.65). 07/2012; 86(19):10857-61. DOI: 10.1128/JVI.01414-12
Source: PubMed

ABSTRACT Neutralizing antibody protection against HIV-1 may require broad and potent antibodies targeting multiple epitopes. We tested 7 monoclonal antibodies (MAbs) against 45 viruses of diverse subtypes from early infection. The CD4 binding site MAb NIH45-46W was most broad and potent (91% coverage; geometric mean 50% inhibitory concentration [IC(50)], 0.09 μg/ml). Combining NIH45-46W and a V3-specific MAb, PGT128, neutralized 96% of viruses, while PGT121, another V3-specific MAb, neutralized the remainder. Thus, 2 or 3 antibody specificities may prevent infection by most HIV-1 variants.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Chimeric SIV/HIV (SHIV) infection of macaques is commonly used to model HIV-1 transmission and pathogenesis in humans. Despite the fact that SHIVs encode SIV antagonists of the known macaque host restriction factors, these viruses require additional adaptation for replication in macaques to establish a persistent infection. Additional adaptation may be required in part because macaque CD4 (mCD4) is a suboptimal receptor for most HIV-1 Env variants. This requirement raises the possibility that adaptation of HIV-1 Env to the macaque host leads to selection of variants that lack important biological and antigenic properties of the viruses responsible for the HIV-1 pandemic in humans. Here, we investigated whether this adaptation process leads to changes in the antigenicity and structure of HIV-1 Env. For this purpose, we examined how two independent mutations that enhance mCD4-mediated entry, A204E and G312V, impact antibody recognition in the context of seven different parental HIV-1 Envs from diverse subtypes. We also examined HIV-1 Env variants from three SHIVs that had been adapted for increased replication in macaques. Our results indicate that these different macaque-adapted variants shared common features including resistance to antibodies directed to quaternary epitopes and sensitivity to antibodies directed to epitopes in the variable domains (V2 and V3) that are buried in the parental, un-adapted Envs. Collectively, these findings suggest that adaptation to mCD4 results in conformational changes that expose epitopes in the variable domains and disrupt quaternary epitopes in the native Env trimer.
    Journal of Virology 11/2014; 89(2). DOI:10.1128/JVI.02680-14 · 4.65 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To protect against HIV infection, passively transferred and/or vaccine-elicited neutralizing antibodies (NAbs) need to effectively target diverse subtypes that are transmitted globally. These variants are a limited subset of those present during chronic infection and display some unique features. In the case of mother-to-child transmission (MTCT), transmitted variants tend to be resistant to neutralization by maternal autologous NAbs. To investigate whether variants transmitted during MTCT are generally resistant to HIV-1-specific NAbs, 107 maternal or infant variants representing the dominant HIV-1 subtypes were tested against six recently identified HIV-1-specific broadly neutralizing monoclonal antibodies (bNAbs), NIH45-46W, VRC01, PGT128, PGT121, PG9 and PGT145. Infant and maternal variants did not differ in their neutralization sensitivity to individual bNAbs, nor did viruses from transmitting versus nontransmitting mothers, although there was a trend for viruses from transmitting mothers to be less sensitive overall. No single bNAb neutralized all viruses, but a combination of bNAbs that target distinct epitopes covered 100% of the variants tested. Compared with heterosexually transmitted variants, vertically transmitted variants were significantly more sensitive to neutralization by PGT128 and PGT121 (P = 0.03 in both cases), but there were no differences for the other bNAbs. Overall, subtype A variants were significantly more sensitive to NIH45-46 (P = 0.04), VRC01 (P = 0.002) and PGT145 (P = 0.03) compared with the nonsubtype A and less sensitive to PGT121 than subtype Cs (P = 0.0001). A combination of bNAbs against distinct epitopes may be needed to provide maximum coverage against viruses in different modes of transmission and diverse subtypes.
    AIDS (London, England) 06/2013; 27(10):1535-44. DOI:10.1097/QAD.0b013e32835faba5 · 6.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The isolation of broadly neutralizing HIV-1 monoclonal antibodies (mAbs) to distinct epitopes on the viral envelope glycoprotein (Env) provides the potential to use combinations of mAbs for prevention and treatment of HIV-1 infection. Since many of these mAbs have been isolated in the last few years, the potency and breadth of mAb combinations has not been well characterized. In two parallel experiments, we examined the in vitro neutralizing activities of double, triple and quadruple mAb combinations targeting four distinct epitopes, including the CD4-binding site, the V1V2-glycan region, the V3-glycan supersite and the gp41 membrane-proximal external region (MPER), using a panel of 125 Env-pseudotyped viruses. All mAb combinations showed substantially improved neutralization breadth compared to the corresponding single mAbs, while the neutralization potency of individual mAbs was maintained. At an IC50 cutoff of 1 μg/ml per antibody, double mAb combinations neutralized 89-98% of viruses, and triple combinations neutralized 98-100%. Overall the improvement of neutralization breadth was closely predicted by an additive effect model and explained by complementary neutralization profiles of antibodies recognizing distinct epitopes. Subtle but consistent favorable interactions were observed in some mAb combinations whereas less favorable interactions were observed on a small subset of viruses that are highly sensitive to V3-glycan mAbs. These data demonstrate favorable in vitro combinations of broadly neutralizing HIV-1 mAbs and suggest that such combinations could have utility for HIV-1 prevention and treatment. Over the last five years, numerous broadly reactive HIV-1 neutralizing mAbs have been isolated from B-cells of HIV-1 infected donors. Each of these mAbs binds to one of the major vulnerable sites (epitopes) on the surface of the viral envelope glycoprotein. Since antibodies to distinct viral epitopes could theoretically act together to provide greater potency and breadth of virus neutralization, we tested physical mixtures of double, triple and quadruple combinations of neutralizing mAbs targeting four major epitopes on the HIV-1 Env. When tested together, antibody combinations showed substantially improved neutralization breadth compared to single mAbs. This improvement could be explained by the complementary neutralization profiles of individual mAbs. We further demonstrated that each antibody maintained its full neutralization potency when used in combination with other mAbs. These data provided a rationale for clinical use of antibody based combinations for HIV-1 prevention and therapy. Copyright © 2014, American Society for Microbiology. All Rights Reserved.
    Journal of Virology 12/2014; 89(5). DOI:10.1128/JVI.03136-14 · 4.65 Impact Factor


Available from